SOPHiA GENETICS (SOPH) EBITDA Margin (2020 - 2025)

SOPHiA GENETICS has disclosed EBITDA Margin across 6 years of filings, most recently posting 85.3% for Q4 2025.

• EBITDA Margin for Q4 2025 came in at 85.3%, down 3426.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 91.76% (down 250.0% YoY), and the FY2025 annual result was 91.76%, down 3011.0% from the prior year.
• EBITDA Margin came in at 85.3% for Q4 2025 at SOPHiA GENETICS, up from 91.78% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 51.04% in Q4 2024 to a low of 197914856.65% in Q3 2021.
• The 5-year median for EBITDA Margin is 115.78% (2024), against an average of 9895864.4%.
• Across the five-year window, EBITDA Margin slumped 2000000000 bps in 2021 and soared 2000000000 bps in 2022, its largest moves.
• SOPHiA GENETICS's EBITDA Margin stood at 192.09% in 2021, then jumped by 41 bps to 112.69% in 2022, then soared by 37 bps to 71.25% in 2023, then climbed by 28 bps to 51.04% in 2024, then slumped by 67 bps to 85.3% in 2025.
• The last three EBITDA Margin figures came in at 85.3% (Q4 2025), 91.78% (Q3 2025), and 100.92% (Q2 2025), per Business Quant data.